The data reveals that inhibiting the NLRP3 inflammasome with MCC950 and administration of the IL-1 receptor antagonist Anakinra prevent OHC loss in CSOM, and therefore shows an ability to cross the blood labyrinthine barrier. This evidence concerns the gene NLRP3 and chronic purulent otitis media.